HealthDay News — COVID-19 vaccination before and during pregnancy is associated with detectable maternal anti-spike immunoglobulin (Ig)G levels at delivery, according to a study published online Dec. 28 in Obstetrics & Gynecology.

Yawei J. Yang, M.D., Ph.D., from Weill Cornell Medicine in New York City, and colleagues conducted a retrospective cohort study involving women with self-reported COVID-19 vaccination, including a booster dose before or during pregnancy. The association between timing of maternal vaccination and maternal and umbilical cord anti-spike IgG levels was examined.

Data were included from 1,359 vaccinated pregnant women, 20 of whom received a booster dose, and from 1,362 umbilical cord samples. The researchers found that among fully vaccinated women, maternal anti-spike IgG levels were detectable at delivery regardless of timing of vaccination throughout pregnancy; the highest anti-spike IgG levels in maternal and umbilical cord blood were seen in association with early third-trimester vaccination. Comparable maternal and cord blood antibody response was achieved with vaccination in early pregnancy among women with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and with third-trimester vaccination among pregnant women without a history of SARS-CoV-2 infection. Maternal anti-spike IgG levels were greater in association with a booster dose in the third trimester than with third-trimester vaccination in women with or without history of SARS-CoV-2 infection.

Continue Reading

“Because immune correlates of protection are not well established at this time, following the recommended vaccination strategy is the optimal approach to protecting pregnant women and their fetuses from COVID-19,” the authors write.

Abstract/Full Text